Search results for "Blood Coagulation Factors"

showing 8 items of 28 documents

Health status and quality of life of elderly persons with severe hemophilia born before the advent of modern replacement therapy

2009

SUMMARY BACKGROUND: More and more people with severe hemophilia reach an old age thanks to an effective treatment. There is no information on the health status and quality of life of elderly people with hemophilia born at a time when replacement therapy was hardly available. METHODS: Italian patients with severe hemophilia, aged >or=65 years and hence born in 1942 or earlier, were compared with elderly men without bleeding disorders matched for age, sex, geography and social status. The following aspects were evaluated: concomitant illness, orthopedic status, physical functioning and cognitive status. Measurements of generic and disease-specific health-related quality of life were also obta…

Malemedicine.medical_specialtyPediatricshamophilia healt status agingActivities of daily livingHealth StatusPopulationActivities of Daily Living; Aged; Blood Coagulation Factors; Hemophilia A; Humans; Italy; Male; Health Status; Quality of LifeHemophilia ASettore MED/15 - Malattie Del SangueQuality of lifehemic and lymphatic diseasesArthropathyActivities of Daily LivingMedicineHumanseducationDepression (differential diagnoses)Agededucation.field_of_studybusiness.industryHematologymedicine.diseaseBlood Coagulation FactorsItalyConcomitantOrthopedic surgeryPhysical therapyQuality of LifebusinessSocial status
researchProduct

Irreversible gelation of thermally unfolded proteins:structural and mechanical properties of lysozyme aggregates

2010

The formation of protein aggregates is important in many fields of life science and technology. The morphological and mechanical properties of protein solutions depend upon the molecular conformation and thermodynamic and environmental conditions. Non-native or unfolded proteins may be kinetically trapped into irreversible aggregates and undergo precipitation or gelation. Here, we study the thermal aggregation of lysozyme in neutral solutions. We characterise the irreversible unfolding of lysozyme by differential scanning calorimetry. The structural properties of aggregates and their mechanisms of formation with the eventual gelation are studied at high temperature by spectroscopic, rheolog…

Models MolecularProtein FoldingCircular dichroismGelationProtein ConformationDiffusionBiophysicsProtein aggregationUnfoldingchemistry.chemical_compoundDifferential scanning calorimetryProtein structureAnimalsQuantitative Biology::BiomoleculesChemistryPrecipitation (chemistry)Circular DichroismTemperaturePercolationGeneral MedicineBlood Coagulation FactorsSettore FIS/07 - Fisica Applicata(Beni Culturali Ambientali Biol.e Medicin)Thermal irreversibilityCrystallographyChemical physicsThermodynamicsMuramidaseProtein foldingLysozymeProtein aggregation
researchProduct

Hereditary combined deficiency of the vitamin K-dependent clotting factors

2010

Abstract Hereditary combined vitamin K-dependent clotting factors deficiency (VKCFD) is a rare congenital bleeding disorder resulting from variably decreased levels of coagulation factors II, VII, IX and X as well as natural anticoagulants protein C, protein S and protein Z. The spectrum of bleeding symptoms ranges from mild to severe with onset in the neonatal period in severe cases. The bleeding symptoms are often life-threatening, occur both spontaneously and in a surgical setting, and usually involve the skin and mucosae. A range of non-haemostatic symptoms are often present, including developmental and skeletal anomalies. VKCFD is an autosomal recessive disorder caused by mutations in …

Vitaminmedicine.medical_specialtyVitamin KCoagulation Factor Deficiencylcsh:MedicineReviewGastroenterologyProtein SProtein SSettore MED/15 - Malattie Del Sanguechemistry.chemical_compoundBlood Coagulation Disorders InheritedInternal medicineVitamin K deficiencymedicineHumansGenetics(clinical)Pharmacology (medical)VITAMIN K DEPENDENT CLOTTING FACTORS RARE INHERITED BLEEDING DISORDERSCongenital Bleeding DisorderGenetics (clinical)Medicine(all)Clotting factorbiologybusiness.industrylcsh:RVitamin K2WarfarinInfant NewbornGeneral MedicineBlood Proteinsmedicine.diseaseBlood Coagulation FactorsRecombinant ProteinschemistryCarbon-Carbon LigasesImmunologybiology.proteinVitamin K Deficiencybusinessmedicine.drugProtein C
researchProduct

The Evolution of Hemophilia Care: Clinical and Laboratory Advances, Opportunities, and Challenges

2020

AbstractHemophilia A (HA) and B (HB) are X-linked bleeding disorders caused by mutations in the F8 or F9 gene that result in the absence, or reduced activity, of the corresponding clotting factor. The severity of bleeding and related complications is proportional to the amount of residual circulating functional factor. The development of a safe and effective hemophilia treatment lasted several decades and has been mainly based on clotting factor replacement. Advances in the engineering and manufacturing of clotting concentrates have led to the widespread availability of extended half-life products that reduced the number of intravenous infusions needed to achieve adequate trough levels. The…

medicine.medical_specialtyAcetylgalactosamineInjections SubcutaneousLipoproteinsHemorrhage030204 cardiovascular system & hematologyAntibodies Monoclonal HumanizedHemophilia AHemophilia BSeverity of Illness IndexDisease courseFactor IX03 medical and health sciencesRoute of administrationLife Expectancy0302 clinical medicineAntibodies BispecificmedicineHumansRNA Small InterferingInfusions IntravenousIntensive care medicineFactor IXClotting factorClinical Trials as TopicFactor VIIICoagulantsbusiness.industryGenetic TherapyHematologyIntravenous InfusionsHistory 20th CenturyBlood Coagulation FactorsLaboratoriesbusiness030215 immunologymedicine.drugHämostaseologie
researchProduct

Combined use of antifibrinolytics and activated prothrombin complex concentrate (aPCC) is not related to thromboembolic events in patients with acqui…

2019

Antifibrinolytics combined with aPCC are not routinely administered to patients with acquired hemophilia A due to increased thrombotic risk. This association normalizes clot stability, and improves the efficacy of therapy, but can increase the risk of severe side effects. Due to these premises it has always raised doubts and perplexities in the clinics. We now report the data of the "FEIBA® on acquired haemophilia A Italian Registry (FAIR Registry)", a retrospective-prospective study that included 56 patients. This is the first study that assessed the clinical response of the combination of aPCC and antifibrinolytic agents in patients with acquired haemophilia A. A total of 101 acute bleeds…

medicine.medical_specialtyAntifibrinolyticmedicine.drug_classHemorrhage030204 cardiovascular system & hematologyHemophilia APremises03 medical and health sciences0302 clinical medicineDrug TherapyThromboembolismAntifibrinolytic agentInternal medicineActivated prothrombin complex concentrateAcquired haemophiliaThromboembolic riskHumansMedicineIn patientRegistries030212 general & internal medicineAcquired haemophilia AHematologybusiness.industryHematologyAcquired haemophilia A; Activated prothrombin complex concentrate; Antifibrinolytics; Thromboembolic risk; Antifibrinolytic Agents; Blood Coagulation Factors; Cardiovascular Diseases; Drug Therapy Combination; Hemophilia A; Hemorrhage; Humans; Registries; ThromboembolismAntifibrinolytic AgentsBlood Coagulation FactorsClinical trialTolerabilityCardiovascular DiseasesCombinationAntifibrinolyticDrug Therapy CombinationAntifibrinolyticsCardiology and Cardiovascular Medicinebusiness
researchProduct

Acquired haemophilia in cancer: A systematic and critical literature review

2017

Aim There is a paucity of data on the clinical presentation and management of cancer patients with acquired haemophilia (AH), we here report a systematic literature review on acquired haemophilia in the context of cancer. Methods Treatment outcomes of AH were defined as complete response (CR), partial response (PR) or no response (NR), based on inhibitor eradication, coagulation factor VIII levels and bleeding control. Reported deaths were either related to cancer or bleeding. Results Overall, 105 cases were collected and analyzed according to classification of cancer and efficacy of treatments for inhibitor and malignancy. The mean age was 68 years for both males (range 37-86 years) and fe…

medicine.medical_specialtyContext (language use)Antineoplastic AgentsFactor VIIa030204 cardiovascular system & hematologyMalignancyHemophilia AGastroenterology03 medical and health sciences0302 clinical medicineAdrenal Cortex HormonesInternal medicineNeoplasmsAcquired haemophiliamedicineHumanscancerhaematological malignancyGenetics (clinical)Blood Coagulation Factor Inhibitorstreatmentbusiness.industryIncidence (epidemiology)AutoantibodyCancerHematologyGeneral Medicinemedicine.diseasebleedingBlood Coagulation FactorsRecombinant ProteinsSurgeryinhibitordiagnosiSystematic reviewTreatment Outcome030220 oncology & carcinogenesisHematologic Neoplasmsacquired haemophilabusinessHaematological malignancy
researchProduct

Hereditary angioneurotic oedema and blood-coagulation: interaction between C1-esterase-inhibitor and the activation factors of the proteolytic enzyme…

1983

C-1-inactivator (C-1-INA) does not only exert its important inhibitory functions in the complement system but also in the first step in the activation of the coagulation, fibrinolytic and kallikrein system. We therefore determined in nine patients with hereditary angioneurotic oedema (HANE) with obvious quantitative or functional defects of C-1-INA, and one further patient with Quincke-type oedema of different origin, the coagulation factors of the initial phase such as Hageman factor, plasma thromboplastin antecedent (PTA) and high molecular weight kininogen (HMWK). These factors were further correlated with the concentration as well as functional activity of C-1-INA. Nine of ten patients …

medicine.medical_specialtyHigh-molecular-weight kininogenInternal medicineDrug DiscoverymedicineHumansAngioedemaFactor XIBlood CoagulationGenetics (clinical)Factor XIFactor XIIComplement C1sChemistryKininogensProteolytic enzymesGeneral MedicineKallikreinMolecular medicineBlood Coagulation FactorsComplement systemEnzyme ActivationEndocrinologyCoagulationFactor XIIMolecular MedicinePeptide HydrolasesKlinische Wochenschrift
researchProduct

Interaction between C1-INA, coagulation, fibrinolysis and kinin system in hereditary angioneurotic edema (HANE) and urticaria.

1984

The C1-inactivator plays an important role not only in the initial phases of the complement system, but also in those of the coagulation, fibrinolysis and kinin systems. The present study was concerned with the reciprocal influence of decreased C1-inactivator levels in patients with hereditary angioneurotic edema (HANE, HAE). In 13 HANE-I patients there were significantly increased levels of the coagulation factors XII, XI, V, of plasminogen and of alpha 2-antiplasmin, while the factors IX and VII were decreased. Conversely, it emerged that in patients with markedly raised prephase factor levels, angioneurotic edema occurred in the presence of normal or only slightly decreased C1-inactivato…

medicine.medical_specialtyUrticariaHereditary angioneurotic edemamedicine.medical_treatmentDermatologyKininsComplement C1 Inactivator Proteinschemistry.chemical_compoundInternal medicineEdemaFibrinolysismedicineHumansAngioedemaFactor XIIAngioedemaFactor VIIbusiness.industryFibrinolysisGeneral MedicineKininBlood Coagulation FactorsEndocrinologyCoagulationchemistryImmunologymedicine.symptombusinessArchives of dermatological research
researchProduct